In vitro antifungal potency of the moronecidin-like peptide against Candida albicans, Candida glabrata, and Candida tropicalis.

IF 1.3 Q4 MICROBIOLOGY

Iranian Journal of Microbiology Pub Date : 2023-06-01 DOI:10.18502/ijm.v15i3.12907

Nasrin Amirrajab, Seyed Amin Ayatollahi Mousavi, Behrooz Taheri, Samira Salari, Noor Ali Ahmadi Sarsahra

{"title":"In vitro antifungal potency of the moronecidin-like peptide against Candida albicans, Candida glabrata, and Candida tropicalis.","authors":"Nasrin Amirrajab, Seyed Amin Ayatollahi Mousavi, Behrooz Taheri, Samira Salari, Noor Ali Ahmadi Sarsahra","doi":"10.18502/ijm.v15i3.12907","DOIUrl":null,"url":null,"abstract":"Background and objectives: The aim of this study was to investigate the in vitro antifungal potency of the moronecidin-like peptide against Candida albicans, Candida glabrata, and Candida tropicalis.Materials and methods: To evaluate the antifungal effect of moronecidin-like peptide, the protocol presented in CLSI M27-A3 and CLSI M27-S4 was used and the minimum inhibitory concentration was determined.Results: The minimum inhibitory effect of moronecidin-like peptide composition was 8 µg/ml for Candida tropicalis and Candida albicans and 32 µg/ml for Candida glabrata. The MIC of nystatin was determined to be 1.25 µg/ml for Candida glabrata and Candida albicans and 0.625 µg/ml for Candida tropicalis strains. The MFC composition of the moronecidin-like peptide was determined for Candida tropicalis and Candida albicans strains 8 µg/ml and for Candida glabrata strain 64 µg/ml. The results of cytotoxicity and hemolysis of the moronecidin peptide test on macrophage showed that moronecidin peptide has no cytotoxicity and toxicity properties.Conclusion: According to the results of the present study, the moronecidin-like peptide could be a new strategy in the treatment of infections caused by Candida strains. The discovery of the exact mechanism of which requires extensive clinical studies in this field.","PeriodicalId":14633,"journal":{"name":"Iranian Journal of Microbiology","volume":"15 3","pages":"456-461"},"PeriodicalIF":1.3000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/c9/IJM-15-456.PMC10336287.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijm.v15i3.12907","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objectives: The aim of this study was to investigate the in vitro antifungal potency of the moronecidin-like peptide against Candida albicans, Candida glabrata, and Candida tropicalis.

Materials and methods: To evaluate the antifungal effect of moronecidin-like peptide, the protocol presented in CLSI M27-A3 and CLSI M27-S4 was used and the minimum inhibitory concentration was determined.

Results: The minimum inhibitory effect of moronecidin-like peptide composition was 8 µg/ml for Candida tropicalis and Candida albicans and 32 µg/ml for Candida glabrata. The MIC of nystatin was determined to be 1.25 µg/ml for Candida glabrata and Candida albicans and 0.625 µg/ml for Candida tropicalis strains. The MFC composition of the moronecidin-like peptide was determined for Candida tropicalis and Candida albicans strains 8 µg/ml and for Candida glabrata strain 64 µg/ml. The results of cytotoxicity and hemolysis of the moronecidin peptide test on macrophage showed that moronecidin peptide has no cytotoxicity and toxicity properties.

Conclusion: According to the results of the present study, the moronecidin-like peptide could be a new strategy in the treatment of infections caused by Candida strains. The discovery of the exact mechanism of which requires extensive clinical studies in this field.

Abstract Image

查看原文本刊更多论文

摩罗菌素样肽对白色念珠菌、光秃念珠菌和热带念珠菌体外抗真菌效力的研究。

背景和目的:本研究的目的是研究摩罗菌素样肽对白色念珠菌、光秃念珠菌和热带念珠菌的体外抗真菌效力。材料与方法:采用CLSI M27-A3和CLSI M27-S4中提出的方案评价moronecidin-like peptide的抑菌效果，并测定其最低抑菌浓度。结果:绿僵菌素样肽组合物对热带念珠菌和白色念珠菌的最小抑制作用为8µg/ml，对光滑念珠菌的最小抑制作用为32µg/ml。光秃假丝酵母和白色假丝酵母制霉菌素的MIC分别为1.25µg/ml和0.625µg/ml。热带念珠菌和白色念珠菌菌株的MFC组成为8µg/ml，光秃念珠菌菌株的MFC组成为64µg/ml。对巨噬细胞进行细胞毒性和溶血试验，结果表明，其不具有细胞毒性和毒性。结论:根据本研究结果，摩罗菌素样肽可能是治疗念珠菌感染的新策略。发现其确切机制需要在该领域进行广泛的临床研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Iranian Journal of Microbiology MICROBIOLOGY-

CiteScore

2.40

自引率

7.10%

发文量

审稿时长

12 weeks

期刊介绍： The Iranian Journal of Microbiology (IJM) is an international, multi-disciplinary, peer-reviewed journal that provides rapid publication of the most advanced scientific research in the areas of basic and applied research on bacteria and other micro-organisms, including bacteria, viruses, yeasts, fungi, microalgae, and protozoa concerning the development of tools for diagnosis and disease control, epidemiology, antimicrobial agents, clinical microbiology, immunology, Genetics, Genomics and Molecular Biology. Contributions may be in the form of original research papers, review articles, short communications, case reports, technical reports, and letters to the Editor. Research findings must be novel and the original data must be available for review by the Editors, if necessary. Studies that are preliminary, of weak originality or merely descriptive as well as negative results are not appropriate for the journal. Papers considered for publication must be unpublished work (except in an abstract form) that is not under consideration for publication anywhere else, and all co-authors should have agreed to the submission. Manuscripts should be written in English.